证券日报网讯 1月30日，天臣医疗发布2025年年度业绩预告称，公司预计2025年年度归属于母公司所有 者的净利润与上年同期（法定披露数据）相比，将增加3，100.00万元到3，700.00万元，同比增加 59.74%到71.30%。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 1月30日，安旭生物发布公告称，公司于2026年1月30日召开了第三届董事会第三次会 议、第三届董事会审计委员会第三次会议，审议通过了《关于部分募集资金投资项目延期的议案》，同 意将募集资金投资项目"体外诊断试剂以及诊断仪器研发生产项目"原计划达到预定可使用状态日期由 2026年1月调整至2027年1月。 ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook for participation in the upcoming stock issuance [22]. Core Insights - The company is a high-quality orthopedic consumables provider, established in 2015, with a focus on spinal, trauma, and sports medicine products. It ranks third in the domestic market for spinal vertebroplasty systems and sixth for spinal implant devices as of 2023 [3][7]. - The company has a competitive advantage in core technologies, with a total of 108 patents, including 41 invention patents, and has established a nationwide sales network [3][7]. - Revenue for 2024 is projected at 275 million yuan, with a slight decline over the past three years at a CAGR of -1.9%. However, non-collection products are expected to grow rapidly, potentially becoming a new growth driver [8][22]. - The company plans to use the raised funds primarily for expanding production capacity in orthopedic consumables, as well as for building a research and development center and marketing network [9][22]. Summary by Sections 1. Company Overview - The company specializes in orthopedic consumables and aims to provide comprehensive solutions for orthopedic surgeries. It has a diverse product matrix and a strong focus on R&D and customer service [3][7]. 2. Issuance Plan - The new stock issuance will adopt a direct pricing method, with an issue price of 7.67 yuan per share. The initial issuance scale is 29.53 million shares, accounting for 25% of the total post-issue share capital, with an expected market capitalization of 906 million yuan [12][13]. 3. Industry Situation - The aging population is driving an increase in the incidence of orthopedic diseases. The proportion of the population aged 65 and above reached 15.64% in 2022, up 5.17% from 2015. This demographic shift is expected to increase the demand for orthopedic products [16][14]. 4. Competitive Advantages - The company has developed a comprehensive product matrix that covers various orthopedic clinical indications. It has established a robust sales network across all provinces in China, enhancing its market presence and customer relationships [17][3]. 5. Comparable Companies - The company’s financial metrics, including a projected gross margin of 58.05% for 2024, are competitive compared to peers in the industry. The average PE ratio of comparable companies is 60, while the company’s PE ratio is significantly lower at 11.65 [21][23]. 6. Subscription Analysis - The company is positioned as a leading player in the medical dressing market, with strong competitive advantages in various segments. The current production capacity is highly utilized, and the planned expansion is expected to unlock growth potential [22].

报告期内，公司归属于母公司所有者的净利润和归属于母公司所有者的扣除非经常性损益的净利润较上 期亏损扩大，主要由于：（一）报告期内，公司主营业务稳定发展，但受行业竞争加剧及医疗集采持续 推进等影响，报告期内自产检测试剂产品增值税税率调整为13%，上述因素叠加导致分子诊断试剂的收 入有所下降。公司持续推进降本增效措施，充分挖掘提质增效潜力，预计综合毛利率较上年同期基本保 持稳定。（二）随着近年来公司加大应收账款的催收力度，长账龄应收账款账面余额逐年减少。报告期 内，公司应收款项减值准备转回较上年同期减少。 格隆汇1月30日丨硕世生物(688399.SH)公布，经财务部门初步测算，预计2025年度实现归属于母公司所 有者的净利润为-2,940万元到-4,400万元，与上年同期（法定披露数据）相比，将扩大亏损2,739.83万元 到4,199.83万元。预计2025年度归属于母公司所有者的扣除非经常性损益的净利润为-8,190万元 到-12,280万元，与上年同期（法定披露数据）相比，将扩大亏损1,006.29万元到5,096.29万元。 ...

Investment Rating - The report indicates a positive outlook for the company, with an expected net profit of 2.02 billion to 2.35 billion yuan for 2025, representing a year-on-year growth of 21.05% to 40.83% [2][3]. Core Insights - The company's performance in 2025 is primarily driven by strong results in its asset management business, despite a decline in its core operations [2][15]. - For the first three quarters of 2025, the company reported revenues of 1.069 billion yuan, with a net profit of 1.589 billion yuan, indicating that total operating costs exceeded revenues [4][5]. - The total assets under management reached 24.122 billion yuan by the end of Q3 2025, highlighting the significant contribution of asset management to the company's profitability [8]. Financial Performance - The expected net profit for 2025 is projected to be between 2.02 billion and 2.35 billion yuan, with a growth rate of 21.05% to 40.83% compared to the previous year [2][3]. - The company’s investment income for the first three quarters of 2025 was 562 million yuan, with fair value changes contributing 1.251 billion yuan, totaling over 1.8 billion yuan in investment-related income [5]. - The company holds trading financial assets worth 10.362 billion yuan, primarily in wealth management products, and other financial assets totaling 10.245 billion yuan, including hedge funds and private equity investments [6][8]. Core Business Performance - The iHealth product line, which includes smart medical devices, has seen a significant decline in revenue, with a 50% drop in the first half of 2025 compared to the previous year [10][11]. - The total revenue from iHealth products for the first three quarters of 2025 was reported at 601 million yuan, reflecting a 49% year-on-year decrease [11][12]. Market Position - The company's price-to-book (PB) ratio is currently at 0.89, indicating that it is trading below its book value, which may attract investors looking for undervalued assets [14]. - The company has substantial cash-like assets totaling 27.6 billion yuan, with short-term borrowings of only 2.334 billion yuan, suggesting a strong liquidity position [14].

公开资料显示，爱得科技主要从事以骨科耗材为主的医疗器械的研发、生产与销售，主要产品包括脊柱 类、创伤类、运动医学等骨科医用耗材以及用于伤口疗愈的创面修复产品。公司坚持以骨科临床需求为 导向，致力于成为国内领先的、覆盖骨科全领域产品矩阵的骨科手术综合解决方案提供商。 1月30日，爱得科技（920180）首次公开发行股票并在北交所上市网上路演在全景网成功举行，公司将 于2月2日开启网上申购。 爱得科技董事长陆强在路演活动中与投资者交流互动时表示，人口老龄化加剧的背景下，中老年人口规 模扩大，整体骨科患病风险加大，对骨科疾病手术治疗的需求持续上升，我国人均可支配收入和人均医 疗消费支出逐年增高，居民医疗消费能力实现持续增长，这带来了骨科医疗服务量的增加，进而促进骨 科疾病的诊疗需求，驱动骨科医疗器械市场扩容。骨科诊疗有一定的刚需属性，合理预计骨科医疗器械 市场未来具有一定的增长空间。 ...

Core Viewpoint - The company DaAn Gene has released its annual performance forecast, expecting a significant net loss for 2025, primarily due to decreased revenue from market demand and policy impacts, despite some improvements in investment income from joint ventures [1] Group 1: Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between -607 million to -865 million yuan [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between -938 million to -658 million yuan [1] Group 2: Revenue and Cost Factors - The decrease in revenue is attributed to market demand, the implementation of centralized procurement, and an increase in the value-added tax rate on self-produced reagent products to 13% [1] - Despite efforts to enhance operational efficiency and reduce costs, the fixed costs such as operational and labor costs remain high, leading to a negative impact on overall gross profit [1] Group 3: Investment and Asset Management - The performance of joint ventures has improved compared to the previous year, resulting in an increase in investment income recognized by the company [1] - The company has strengthened its collection of historical accounts receivable, leading to a reduction in the provision for credit impairment losses compared to the previous year [1] - A comprehensive asset review was conducted, and impairment tests were performed on assets showing signs of impairment, resulting in an increase in the provision for asset impairment losses compared to the previous year [1] Group 4: Non-Recurring Gains - The fair value of other non-current financial assets has increased, contributing to a rise in net profit attributable to shareholders compared to the previous year, with non-recurring gains before tax increasing by approximately 180 million yuan [1]

格隆汇1月30日丨万东医疗(600055.SH)公布，经财务部门初步测算，预计2025年度实现归属于母公司所 有者的净利润为-19,873万元到-25,683万元，与上年同期相比，将出现亏损。预计2025年度实现归属于 母公司所有者的扣除非经常性损益后的净利润为-21,323万元到-27,133万元，与上年同期相比，将出现 亏损。 ...

报告期内，公司归属于母公司所有者的净利润和归属于母公司所有者的扣除非经常性损益的净利润较上 期亏损扩大，主要由于：（一）报告期内，公司主营业务稳定发展，但受行业竞争加剧及医疗集采持续 推进等影响，报告期内自产检测试剂产品增值税税率调整为13%，上述因素叠加导致分子诊断试剂的收 入有所下降。公司持续推进降本增效措施，充分挖掘提质增效潜力，预计综合毛利率较上年同期基本保 持稳定。（二）随着近年来公司加大应收账款的催收力度，长账龄应收账款账面余额逐年减少。报告期 内，公司应收款项减值准备转回较上年同期减少。 格隆汇1月30日丨硕世生物(688399.SH)公布，经财务部门初步测算，预计2025年度实现归属于母公司所 有者的净利润为-2,940万元到-4,400万元，与上年同期（法定披露数据）相比，将扩大亏损2,739.83万元 到4,199.83万元。预计2025年度归属于母公司所有者的扣除非经常性损益的净利润为-8,190万元 到-12,280万元，与上年同期（法定披露数据）相比，将扩大亏损1,006.29万元到5,096.29万元。 ...

2025年，"新质生产力"成为产业界出现频率最高的词汇，而在医疗健康领域，这一概念正落子于具体的 诊疗环节。 通过成熟的商用终端和数字化技术，医疗机构能够将服务边界从医院内部延伸到患者生活中，将分散在 院外的健康数据转化为可用的医疗资源，从某种程度上来说，提升医疗服务能力，除了增加床位之外， 通过技术挖掘数据价值，同样能让有限的资源服务更多的人群。 破局：从"断连"到"互联" 温州市人民医院的冠心病患者董先生（化名），就在近期刚经历了一次险情。 今年51岁的董先生（化名）不久前才完成心脏支架手术，处于出院后的康复期，按照惯例，这个阶段的 患者通常会与医院"失联"，复诊与否全靠自觉。但在一个看似平常的午后，董先生（化名）佩戴的华为 擎云智能穿戴设备在后台捕捉到了一组异常数据：血氧饱和度持续低于90%。 这组数据通过标准接口，实时同步至温州市人民医院的诊后管理平台，几分钟后，医院管理团队的电话 打了进来，医生根据数据指导他进行了紧急干预。 这次及时地处置，规避了一次可能引发心衰或休克的医疗风险。 但这种"幸运"在目前的医疗体系中仍是少数，更多时候，患者离开医院大门，就意味着专业监护的断 档。 董先生（化名）的案例 ...